





MATRIX Stakeholders Consultation Johannesburg, South Africa

5-6 October 2022

DAY 1 – Wednesday, 5 October 2022

| Time | Session | Title |
|---------------|------------|--|
| 08:15-09:00 | | Registration |
| 09:00-09:45 | Session 1 | Welcome and Introductions Nandisile Luthuli Sikwana, Thesla Palanee Phillips, National Department of Health representative |
| CONTEXT | AND SETTIN | G THE STAGE |
| 09:45 -10:15 | Session 2 | Voices that Matter – and Why • Speaking to the HIV prevention needs of young women Chantel Maganye, Sarah Mkhabela • A look at the current HIV prevention landscape Nandisile Luthuli Sikwana |
| 10:15-10:30 | Session 3 | MATRIX: Developing the next generation of HIV prevention products for women Thesla Palanee Phillips |
| 10:30-10-45 | | Tea Break |
| 10:45-11:15 | Session 4 | Understanding the Research & Development Process Thesla Palanee Phillips (15 mins) Questions and Discussion (15 mins) Nandisile Luthuli Sikwana - Facilitator |
| 11:15-12:00 | Session 5 | Conducting early phase and first-in-human studies in sub-Saharan Africa Leila E. Mansoor (15 mins) Experiences as a former Phase 1 trial participant Monica Pule (5 mins) Questions and Discussion (20 mins) Nandisile Luthuli Sikwana - Facilitator |
| SEEKING | STAKEHOLDE | RS' VIEWS AND PERSPECTIVES (PART 1) |
| 12:00-13:00 | Session 6 | Is there a place for new methods and product formulations? Definate Nhamo, Wawira Nyagah - Facilitators |
| 13:00-14:00 | | Lunch |
| SEEKING | STAKEHOLDE | RS' VIEWS AND PERSPECTIVES (PART 2) |
| 14:00 - 15:30 | Session 7 | TAF/EVG Fast-Dissolving Insert What is the TAF/EVG Fast-Dissolving Insert? Meredith Clark (pre-recorded – 10 minutes) MATRIX-001 Phase 1 Study of the TAF/EVG Fast-Dissolving Insert Leila E. Mansoor (10 mins) Open discussion and interactive session (75 mins) Nandisile Luthuli Sikwana, Wawira Nyagah - Facilitators |
| 15:30-15:45 | | Tea Break |

| SEEKING STAKEHOLDERS' VIEWS AND PERSPECTIVES (PART 3) | | | | |
|---|-----------|---|--|--|
| | | One-Month Dapivirine Vaginal Film • What is the one-month dapivirine vaginal film? Lisa Rohan (pre-recorded – 5 minutes) | | |
| 15:45-17:00 | Session 8 | MATRIX-002 Acceptability and Safety Study of Two Prototype Vaginal Films <i>Thesla Palanee Phillips</i> (10 mins) | | |
| | | Open discussion and interactive session (60 mins) | | |
| | | Nandisile Luthuli Sikwana and Definate Nhamo - Facilitators | | |
| 17:00-17:05 | | Closing Remarks for Day One Thesla Palanee Phillips | | |
| 18:30- 21:00 | | Reception and Dinner | | |

DAY 2 – Thursday, 6 October 2022

| Time | Session | Title | | | |
|---|------------|---|--|--|--|
| 09:00-09:30 | Session 1 | Day One Recap and Outstanding Questions Thesla Palanee Phillips Nandisile Luthuli Sikwana - Facilitator | | | |
| SEEKING STAKEHOLDERS' VIEWS AND PERSPECTIVES (PART 4) | | | | | |
| 09:30-10:30 | Session 2 | Non-Antiretroviral (ARV)/Nonhormonal Contraceptive Multipurpose Vaginal Ring (Also called the LAMP-IVR) | | | |
| | | What is the non-ARV/nonhormonal contraceptive multipurpose vaginal ring? Marc Baum (pre-recorded – 10 minutes) | | | |
| | | Open discussion and interactive session (50 mins) Definate Nhamo - Facilitator | | | |
| 10:30-10-45 | | Tea Break | | | |
| 10:45-11:00 | Session 3 | What is Griffithsin Fast-Dissolving Insert? Lisa Haddad (pre-recorded – 5 minutes) What are the Cabotegravir Dissolvable Pellet Implants and the Cabotegravir | | | |
| | | Injectable Depot? Gustavo Doncel (pre-recorded – 10 minutes) | | | |
| SEEVING ST | VEHOLDERS' | Imelda Mahaka - Facilitator | | | |
| SEEKING STAKEHOLDERS' VIEWS AND PERSPECTIVES (PART 5) | | | | | |
| 11:00-11:30 | Session 4 | A few final questions Imelda Mahaka, Wawira Nyagah- Facilitators | | | |
| 11:30-12:00 | Session 5 | What do young women think? What do others think? Wawira Nyagah- Facilitator | | | |
| 12-12:45 | Session 6 | Meeting Evaluation Summary and Next Steps Thesla Palanee Phillips, Nandisile Luthuli Sikwana | | | |
| 13:00-14:00 | | Lunch | | | |
| | | | | | |